Daily Bulletin

Men's Weekly

.

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically

- Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma

MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular...

Read more: PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant...

Business News

3PL Logistics in Australia: Strengthening Supply Chains for Growing Businesses

Australia’s vast geography and diverse consumer markets make logistics a critical part of business success. As companies scale and customer expectations rise, many turn to 3pl logistics australia to...

Daily Bulletin - avatar Daily Bulletin

Why Choosing The Right Shopify Web Developer Shapes Long-Term Ecommerce Success

Building a Shopify store that performs reliably over time requires more than surface-level setup. Working with an experienced Shopify web developer ensures that the platform is configured with inten...

Daily Bulletin - avatar Daily Bulletin

Robot Trading and Automation: Does Automated Trading Really Work?

In today’s fast-moving financial markets, many new and experienced traders wonder whether automated trading systems — often called trading robots, expert advisors (EAs), or algorithmic bots — can real...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business